Int J Antimicrob Agents by Stockmann, Chris et al.
Characteristics of antimicrobial studies registered in the USA 
through ClinicalTrials.Gov
Chris Stockmanna,b,*, Catherine M.T. Sherwina, Krow Ampofoa, Adam L. Hersha, Andrew T. 
Paviaa, Carrie L. Byingtona, Robert M. Warda,b, and Michael G. Spigarellia,b
aDepartment of Paediatrics, University of Utah School of Medicine, Salt Lake City, Utah, USA
bDepartment of Pharmacology/Toxicology, University of Utah College of Pharmacy, Salt Lake 
City, Utah, USA
Abstract
Increasing rates of antimicrobial-resistant infections and the dwindling pipeline of new agents 
necessitate judicious, evidence-based antimicrobial prescribing. Clinical trials represent a vital 
resource for establishing evidence of safety and efficacy, which are crucial to guiding 
antimicrobial treatment decisions. The objective of this study was to comprehensively evaluate the 
characteristics of antimicrobial research studies registered in ClinicalTrials.gov. Primary outcome 
measures, funding sources, inclusion criteria and the reporting of study results were evaluated for 
16 055 antimicrobial studies registered in ClinicalTrials.gov as of mid 2012. Interventional studies 
accounted for 93% of registered antimicrobial studies. Clinical trials of drugs (82%) and biologics 
(9%) were most common. Antibacterial, antiviral and antifungal studies accounted for 43%, 41% 
and 16% of drug trials, respectively. Among interventional drug trials, 73% featured randomised 
allocation to study arms and 71% included measures of safety and/or efficacy as primary 
endpoints. Children were eligible for enrolment in 26% of studies. Among the studies, 60% were 
sponsored primarily by non-profit organisations, 30% by industry and 10% by the federal 
government. Only 7% of studies reported results; however, 71% of these were sponsored primarily 
by industry. Antimicrobial studies commonly incorporated elements of high-quality trial design, 
including randomisation and safety/efficacy endpoints. Publication of study results and updating 
of ClinicalTrials.gov should be encouraged for all studies, with particular attention paid to 
research sponsored by non-profit organisations and governmental agencies. Leveraging the 
application of these data to guide the careful selection of antimicrobial agents will be essential to 
preserve their utility for years to come.
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1. Introduction
Antibiotic-resistant pathogens are on the rise globally and limit the effectiveness of existing 
antibiotics [1]. The economic burden associated with these infections has been estimated at 
$21–34 billion annually in the USA [2]. Although reports from the Infectious Diseases 
Society of America (IDSA) and the US Centers for Disease Control and Prevention (CDC) 
highlight the urgent need for new antimicrobial agents with novel mechanisms of action 
[3,4], few new anti-infective agents are currently under development. A recent study found 
nine new intravenous compounds active against Gram-negative bacilli that were in phase 2 
or 3 trials and only two of them featured novel mechanisms of action [5]. In addition, the 
emergence of antiviral-resistant influenza, herpes simplex virus, varicella–zoster virus, 
human immunodeficiency virus and others provides a sobering reminder of the clinical and 
public health implications of antiviral resistance [6]. Collectively, these reports underscore 
the need to spur antimicrobial development and simultaneously enhance the dissemination 
of evidence-based antimicrobial prescribing with appropriate stewardship.
No studies to date have comprehensively evaluated the state of antimicrobial clinical 
research, largely owing to the difficulty in evaluating such a large and diverse number of 
studies. However, DiMasi et al. calculated the probability of achieving clinical approval for 
several classes of drugs in development from 1993–2009 and found that systemic anti-
infective agents feature the highest clinical approval success rate (24%) [7]. Conversely, 
these drugs have the lowest likelihood of progressing beyond phase 1/2 trials (58%). This 
may reflect the availability of definitive endpoints in anti-infective trials, which can be used 
to abandon drugs with unfavourable safety and efficacy profiles.
Recognising the need to provide a central resource for identifying and tracking clinical trials 
conducted in the USA, Congress mandated the creation of a clinical trials registry in 1997 
[8]. The ClinicalTrials.gov registry was created and released in 2000 by the National 
Institutes of Health (NIH) National Library of Medicine (NLM) with input from the US 
Food and Drug Administration (FDA) and others [9]. In 2005, the International Committee 
of Medical Journal Editors (ICMJE) required the registration of clinical trials in the 
ClinicalTrials.gov registry prior to publication [10]. More recently, in 2007 the FDA 
expanded the purview of ClinicalTrials.gov to include the registration of nearly all non-
phase 1 drug and device trials [11]. The law also requires that study sponsors or their 
designees report key study design characteristics, basic results and adverse events [12].
In this study, we examined fundamental characteristics of observational and interventional 
studies of antimicrobial agents registered in the USA. The objective of this study was to 
report the extent to which antimicrobial trials have incorporated characteristics that are 
desirable for generating high-quality evidence, including randomisation, blinding, criteria 
for participation, primary endpoint selection, disclosure of study results and primary funding 
sources.
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ClinicalTrials.gov is a publicly accessible, national registry of research studies that is 
maintained by the NIH’s NLM, in collaboration with the FDA. The registry includes data on 
federally and privately sponsored clinical studies of a wide range of diseases and conditions. 
As of mid 2012, ClinicalTrials.gov contained information on 131 072 studies [13]. These 
trials were conducted in all 50 states and in 179 countries.
2.2. Study selection
A query of ClinicalTrials.gov was performed using a registry search function with the 
following keywords: ‘anti-infective’, ‘antimicrobial’, ‘antibiotic’, ‘antibacterial’, ‘antiviral’ 
and ‘antifungal’. No restrictions were applied on the basis of trial registration date, study 
inclusion/exclusion criteria or availability of study results. Separate databases were 
compiled to enable comparisons between antibacterial, antiviral and antifungal agents. All 
data were downloaded on 11 August 2012.
2.3. Data extraction
Data elements extracted from ClinicalTrials.gov included: a unique trial identifier; study 
title; recruitment status; condition(s) studied; primary purpose of the study; interventional or 
observational status; interventional type (if appropriate); primary funding source; age group 
and sex eligibility criteria; trial phase (0–4); anticipated enrolment size; study design; 
primary endpoint; blinding status; and the availability of study results. Primary funding 
sources were classified as government, industry or non-profit according to the methods 
described by Bourgeois et al. [14].
2.4. Statistical analyses
Descriptive statistics were used to characterise the antimicrobial studies extracted from the 
ClinicalTrials.gov registry. Comparisons between studies of antibacterial, antiviral and 
antifungal agents were conducted using the χ2 test or Fisher’s exact test, as appropriate. 
Continuous variables were compared using the non-parametric Wilcoxon rank-sum test. A 
P-value of <0.05 was considered to be significant. All statistical analyses were performed 
using Stata 11.2 (StataCorp LP, College Station, TX).
3. Results
3.1. Characteristics of all antimicrobial studies
A total of 16 055 antimicrobial studies have been registered in ClinicalTrials.gov since its 
inception in 2000. Overall, 47% have been completed, 25% are actively recruiting 
participants, and the majority of the remaining studies are not yet actively recruiting 
subjects. The most common primary purpose of these antimicrobial studies was research on 
treatment (77%), followed by prevention (8%), basic science investigations (2%), diagnostic 
investigations (1%) and supportive care studies (1%). Interventional studies accounted for 
93% of all antimicrobial studies; observational study designs accounted for the remaining 
7%. Among interventional trials, drugs and biologics dominated, accounting for a combined 
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91% of all interventional studies. Additional interventions and study characteristics are 
featured in Table 1.
3.2. Interventional drug trials
Interventional drug trials of antimicrobial agents accounted for 9% (n = 12 232) of the total 
number of clinical research studies registered in ClinicalTrials.gov among all medical 
specialties. The frequency of antimicrobial drug trials according to their stated primary 
purpose is presented in Table 2. Safety/efficacy were the primary endpoints in 63% of trials, 
followed by pharmacokinetics/pharmacodynamics (9%) and bioavailability/bioequivalence 
trials (2%). Allocation to intervention arms via randomisation was common (73%) among 
interventional antimicrobial drug trials. The most frequent allocation scheme was parallel 
group assignment (53%), followed by single group assignment (38%), cross-over 
assignment (8%) and factorial assignment (2%). Trials were evenly split between early 
phase 0–2 (25%), phase 2–3 studies (37%) and phase 3–4 studies (38%). The median 
estimated sample size was 66 participants (interquartile range 30–200 participants). Overall, 
26% of interventional antimicrobial drug trials included children and adults. Only 5% 
enrolled children exclusively.
A comparison of trial characteristics among antibacterial, antiviral and antifungal agents is 
presented in Table 3. Double-blinded trials were far more frequent among studies of 
antifungal agents compared with studies of antibacterials or antivirals (P < 0.001). In 
contrast, randomisation status, interventional group assignment, trial phase and participant 
inclusion criteria were similar among all antimicrobial drug studies.
3.3. Primary funding sources
Overall, the primary funding sources of antimicrobial studies in the USA are non-profit 
organisations (60%), industry (30%) and the federal government (10%). Among 
interventional drug trials, 35% were funded primarily by industry sources. This was 
comparable with the funding provided by governmental sources (35%). Table 4 features a 
comparison of the study design characteristics of interventional antimicrobial drug trials 
according to their primary funding source. Studies of antibacterial agents were more 
commonly funded by non-profit organisations (64%) compared with antiviral (52%) and 
antifungal (56%) agents (P < 0.001). Thirteen percent of studies on antiviral agents were 
primarily funded by governmental agencies, which was slightly higher than the proportion 
of antibacterial (7%) and antifungal (8%) agents (P < 0.001).
Trials that included children were substantially more likely to have been primarily funded by 
governmental agencies compared with industry sources (18% vs. 7%; P < 0.001). However, 
funding of paediatric and adult trials was evenly split among studies sponsored primarily by 
non-profit organisations.
3.4. Availability of study results
For all antimicrobial studies, only 7% have reported results in ClinicalTrials.gov. Among 
completed interventional drug trials of antimicrobial agents, 12% have made their results 
available. Fig. 1 shows the availability of study results for completed interventional drug 
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trials according to their primary funding source, trial phase, age groups eligible for 
enrolment and endpoint classification. The majority (71%) of trials with results available 
were funded primarily by industry sources. Only 3% of government and non-profit 
sponsored studies had reported results compared with 15% of industry sponsored studies (P 
< 0.001). There was no difference in the proportion of studies with results reported between 
paediatric and adult trials or among different antimicrobial types.
4. Discussion
More than 16 000 antimicrobial studies have been registered in ClinicalTrials.gov since 
2000. Collectively, evaluation of antimicrobial agents accounts for nearly 1 in 10 of all 
registered clinical research studies. The vast majority were interventional trials of drugs and 
biologics. Primary endpoints frequently included markers of safety and efficacy. Nearly 
75% of interventional drug trials were randomised and 26% recruited children in addition to 
adults. Funding for antimicrobial studies varied, with 60% of studies primarily sponsored by 
non-profit organisations, 30% from industry and 10% from the federal government. Across 
all completed interventional drug trials, only 12% have been updated with study results 
and/or publications and, notably, the vast majority of the studies with results available were 
sponsored primarily by industry sources.
Randomisation is appropriately regarded as a hallmark of a high-quality clinical trial [15]. 
The current study shows that nearly three-quarters of antimicrobial drug trials incorporated 
randomisation, more than one-quarter were double-blinded and the majority included a 
primary safety/efficacy endpoint. A further 28% of registered trials were double-blinded. 
These values are higher than have been reported among oncology trials and are comparable 
with cardiovascular and mental health studies [16]. The FDA requires that ‘pivotal’ trials 
include primary safety and efficacy endpoints, as these clinical studies ‘form the basis for 
FDA’s finding that a [drug or device] is safe and effective for its intended use’ [17]. On the 
other hand, consistent with previous reports, there were few pharmacokinetic/
pharmacodynamic studies registered in ClinicalTrials.gov [14,18]. This is likely due to the 
fact that many safety and efficacy studies include a pharmacokinetic assessment or 
extrapolate from earlier studies [19]. Other possibilities, however, include a true deficiency 
of pharmacokinetic studies, a lack of registration of such trials or a combination of the 
above.
Paediatric trials are often regarded as challenging owing to scientific, ethical and practical 
considerations [20]. This perception stems from the physiological changes associated with 
growth and development, the vulnerable population status afforded to children by federal 
regulations, the low prevalence of many childhood diseases, and considerations of market 
size and profitability, among others [21]. Among all interventional trials registered in 
ClinicalTrials.gov, 17% included children <18 years of age from October 2007 through 
September 2010 [16]. In this study, 26% of interventional antimicrobial drug trials enrolled 
children and adults. Only 5% of studies recruited children exclusively. Although this 
compares favourably with drug trials in other disease states, additional work is needed to 
ensure that children are included in clinical trials of antimicrobials so that treatment 
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decisions may be based upon well controlled studies and not naïvely extrapolated from 
adults.
Funding for clinical research on antimicrobial agents is derived from a variety of sources, 
with non-profit organisations as the lead sponsor for three out of every five studies. Industry 
sponsors serve as the primary funding source for 30% of antimicrobial studies and 
governmental agencies sponsor the remaining 10%. When limited to interventional drug 
trials, the proportion of antimicrobial trials led by industry sources rose to 35%. Recent 
reports have claimed that industry has been reluctant to invest in research and development 
toward new antimicrobial agents owing to the size of the generic market, the short duration 
of many antimicrobial regimens, and the potential for the development of resistance, among 
other reasons [22]. Industrial sources were the primary sponsor of 36% of all interventional 
trials registered in ClinicalTrials.gov from 2000–2010 [16]. This indicates that industry 
funding of antimicrobial trials is on par with levels of support seen among studies in other 
disease states and conditions, including cardiology and oncology trials [16].
Although industry-led studies accounted for only 30% of all clinical research on 
antimicrobials registered in ClinicalTrials.gov, 71% of the studies reporting results were 
sponsored primarily by industry. This finding may reflect an association demonstrated by 
previous studies between industry funding and favourable reporting of trial results [23–25]. 
This may indicate that industry sponsors benefit from study completion and the reporting of 
trial results. In this study, we could not assess whether trial outcomes were favourable or 
not. Although not all trials have completed recruitment or had the opportunity to prepare 
data for analysis and publish a manuscript, 15% of studies led by industry have reported 
their results within ClinicalTrials.gov. This compares with 3% of studies funded by non-
profit and governmental sources. As noted by Zarin and Tse, this may reflect strategic study 
design, careful study co-ordination, selective publication, or biases in study conduct and data 
analyses [26]. Although all of these are possible explanations, Ross et al. reported that 
publication patterns are similar for publicly funded and industry-sponsored studies [18]. 
This suggests that reporting requirements for industry-led studies may lead to more 
comprehensive and accurate updating of study results in ClinicalTrials.gov. Regardless, 
there is an urgent need to improve the timely dissemination of study results among all 
antimicrobial studies, especially those funded by non-profit and governmental sources. The 
growth of online-only, open-access, peer-reviewed journals and encouragement from the 
ICMJE has reduced competition for limited print space and fostered the publication of trials 
with negative or inconclusive outcomes [27]. These data are essential for the development of 
new lines of scientific inquiry and the successful translation of research into clinical 
practice.
This study has several limitations. Notably, ClinicalTrials.gov does not capture all clinical 
research studies performed in the USA, as the legal requirement for registration does not 
extend to phase 0–1 trials or non-interventional studies. However, ClinicalTrials.gov 
accounts for >80% of all studies registered in the World Health Organization’s International 
Clinical Trials Registry Platform [16]. Second, the accuracy, validity and completeness of 
the data featured in ClinicalTrials.gov are dependent upon the quality of the information 
entered by the sponsor or their designee. ClinicalTrials.gov does, however, employ an 
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automated evaluation system to alert sponsors when data fields are missing or internally 
inconsistent [12]. Third, the evolution of federal regulations governing the registration and 
reporting of trial results within ClinicalTrials.gov may complicate the interpretation of this 
study’s results, which evaluated all antimicrobial studies registered from 2000–2012. Fourth, 
it was not possible to evaluate the conditions or disease states evaluated in these 
antimicrobial studies. Consequently, it is unknown to what extent these studies are targeting 
the areas of greatest unmet need in infectious diseases research. Lastly, we did not manually 
review the publications associated with studies featured in ClinicalTrials.gov to assess their 
concordance with pre-specified trial endpoints, nor could we ascertain whether the study 
reported positive, negative or inconclusive results.
At a time of increasing antimicrobial resistance and a paucity of new drugs in the pipeline, it 
is more critical than ever that antimicrobial prescribing be based upon evidence of safety 
and efficacy from carefully conducted clinical trials. Here we show that since 2000 more 
than 16 000 antimicrobial studies have been registered in ClinicalTrials.gov. More than 
three-quarters of these studies have been registered with treatment designated as the primary 
purpose. Nearly all interventional drug trials featured a safety and/or efficacy primary 
endpoint and many featured randomised assignment to study arms. Unfortunately, few 
studies have been updated to include results and publications. Of those with results 
available, the majority were sponsored primarily by industry. Publication of study results 
and updating of ClinicalTrials.gov should be encouraged for all studies, with particular 
attention paid to research sponsored by non-profit organisations and governmental agencies. 
These studies will form the basis for evidence-based treatment recommendations and 
professional society guidelines for decades to come. Consequently, we must strive to bridge 
the gap between investigators and the public in order to further clinical research and medical 
progress.
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Availability of study results among completed interventional antimicrobial drug trials by (A) 
clinical trial phase, (B) age groups eligible for enrolment and (C) primary endpoint 
classification.
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Table 1
Clinical trial attributes of antimicrobial studies registered in ClinicalTrials.gov
Characteristic Category Total (N = 16 055) [n (%)]






Active, not recruiting 2398 (15)
Enrolling by invitation 141 (1)
Other 30 (<1)
Primary purpose Treatment 12 382 (77)
Prevention 1219 (8)
Diagnostic 196 (1)
Supportive care 182 (1)
Screening 40 (<1)
Health services research 69 (<1)
Basic science 256 (2)
Educational/counselling 18 (<1)
Missing 1693 (11)
Study design Interventional 14 936 (93)
Observational 1089 (7)
Expanded access 30 (<1)
Intervention a Biologic 1403 (9)
Drug 12 232 (82)
Device 379 (3)
Procedure 362 (2)
Behavioural change 153 (1)
Other 407 (3)
a
Denominator reflects the number of interventional antimicrobial studies (N = 14 936).
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Table 2
Primary purpose of interventional antimicrobial drug trials registered in ClinicalTrials.gov from 2000–2012
Primary purpose n (%)
Industry (N = 4167) NIH (N = 1039) Non-profit a (N = 6869) US federal c (N = 157)
Treatment 3512 (84) 937 (90) 5702 (83) 120 (76)
Prevention 183 (4) 81 (8) 651 (9) 23 (15)
Basic science 121 (3) 1 (<1) 111 (2) 3 (2)
Supportive care 15 (<1) 4 (<1) 106 (2) 0 (0)
Diagnostic 14 (<1) 5 (<1) 68 (1) 1 (1)
Health services research 6 (<1) 1 (<1) 20 (<1) 0 (0)
Screening 4 (<1) 0 (0) 12 (<1) 1 (1)
Education/counselling 2 (<1) 0 (0) 7 (<1) 2 (1)
Missing/unknown 310 (7) 10 (1) 192 (3) 7 (4)




Other US federal agencies, excluding the NIH.
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Table 3
Interventional therapeutic drug trial characteristics by antimicrobial type
Characteristic Category Antimicrobial type
Antibacterials (N = 
5530) a
Antivirals (N = 
5150) a
Antifungals (N = 
2040) a
Allocation status Randomised 2956 (53) 2346 (46) 929 (46)
Non-randomised 1179 (21) 1147 (22) 502 (25)
Unknown/missing 1395 (25) 1657 (32) 609 (30)
Blinding Open 3618 (65) 3396 (66) 316 (15)
Single-blind 209 (4) 69 (1) 59 (3)
Double-blind 1202 (22) 941 (18) 1488 (73)
Unknown/missing 501 (9) 744 (14) 177 (9)
Interventional group Single group 1942 (35) 1661 (32) 810 (40)
Parallel 2441 (44) 2057 (40) 813 (40)
Cross-over 273 (5) 252 (5) 109 (5)
Factorial 62 (1) 60 (1) 28 (1)
Unknown/missing 812 (15) 1120 (22) 280 (14)
Endpoint classification Bioavailability 17 (<1) 15 (<1) 8 (<1)
Bioequivalence 114 (2) 43 (1) 21 (1)
Efficacy 1085 (20) 874 (17) 298 (15)
Pharmacokinetics and/or pharmacodynamics 326 (6) 469 (9) 191 (9)
Safety 391 (7) 551 (11) 168 (8)
Safety/efficacy 2481 (45) 2191 (43) 960 (47)
Unknown/missing 1116 (20) 1007 (20) 394 (19)
Study phase Phase 0, 1, 1/2 1220 (22) 1170 (23) 600 (29)
Phase 2, 2/3 1754 (32) 1933 (38) 582 (29)
Phase 3, 4 1972 (36) 1575 (31) 674 (33)
Unknown/missing 584 (11) 472 (9) 184 (9)
Expected sample size 
[median (IQR)]
66 (32–201) 60 (30–60) 50 (25–145)
Sex Female only 534 (10) 264 (5) 99 (5)
Male only 147 (3) 97 (2) 104 (5)
Both 4842 (88) 4785 (93) 1835 (90)
Unknown/missing 7 (<1) 4 (<1) 2 (<1)
Age groups Children only 294 (5) 176 (3) 107 (5)
Children and adults 1158 (21) 942 (18) 479 (23)
Adults only 4078 (74) 4032 (78) 1454 (71)
Lead funding source Industry 1577 (29) 1801 (35) 717 (35)
Government 406 (7) 671 (13) 161 (8)
Non-profit b 3547 (64) 2678 (52) 1162 (57)
IQR, interquartile range.
a
Data are n (%) unless otherwise stated.
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Not-for-profit organisations.
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Table 4
Characteristics of interventional antimicrobial drug trials according to their primary funding source
Characteristic Category Industry (N = 
4167) b
Non-profit a (N = 
6869) b
Government (N = 
1196) b
Allocation status Randomised 2597 (62) 3534 (51) 405 (34)
Non-randomised 819 (20) 1501 (22) 181 (15)
Unknown/missing 751 (18) 1834 (27) 610 (51)
Blinding Open 2321 (56) 4758 (69) 498 (42)
Single-blind 152 (4) 242 (4) 11 (1)
Double-blind 1387 (33) 1293 (19) 265 (22)
Unknown/missing 307 (7) 576 (8) 422 (35)
Endpoint classification Bioavailability 22 (1) 22 (0) 3 (<1)
Bioequivalence 184 (4) 35 (1) 0 (0)
Efficacy 391 (9) 1781 (26) 206 (17)
Pharmacokinetics and/or pharmacodynamics 513 (12) 368 (5) 148 (12)
Safety 594 (14) 301 (4) 170 (14)
Safety/efficacy 1990 (48) 2865 (42) 327 (27)
Unknown/missing 473 (11) 1497 (22) 342 (29)
Expected sample size, 
median (IQR)





Data are n (%) unless otherwise stated.
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